Skip to main content
. Author manuscript; available in PMC: 2011 Jul 15.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2010 Jan 28;30(4):781–786. doi: 10.1161/ATVBAHA.109.195693

Figure 3.

Figure 3

Intestine-specific LXR agonist promotes RCT in vivo. Wild-type mice (n=5/each group) were treated with indicated drug for 10 days and RCT study was performed with J774 macrophages as described in Methods. (A) FPLC analysis of cholesterol mass profile of pooled 48-hours plasma from wild-type mice treated with indicated drug. (B) FPLC analysis of [3H]-cholesterol profile of pooled 48-hours plasma from wild-type mice treated with indicated drug. (C) [3H]-cholesterol in plasma after macrophages injection. (D) [3H]-cholesterol in liver. (E) [3H]-tracer distribution in feces. *p<0.05, **p<0.01 vs vehicle group. §p<0.05, §§p<0.01 vs GW6340 group. Data are expressed as mean ± SD.